Overall, these adipocytokines may be markers of responsiveness to chemotherapy in ALL, whereas adiponectin and leptin are potential prognostic biomarkers associated with poor outcomes in patients with ALL [134,135]. This evidence concerns the gene LEP and acute lymphoblastic leukemia.